Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable tech monitors SMA babies at home to pinpoint best time for extra treatment

NCT ID NCT07543003

Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up to 60 babies with spinal muscular atrophy (SMA) found at birth, plus 30 healthy babies, for up to 30 months. Researchers use wearable devices worn at home to track muscle development and find when movements start to differ from normal. The goal is to identify the best time to give additional medicines that are being developed to support muscle strength.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants residing in the UK

Ages

Up to 4 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria (Test cohort): 1. Genetically confirmed SMA and number of SMN2 copies available 2. a. Patients identified by NBS and treated with disease modifying therapy (DMT) (2)a,i 4 copies or more of SMN2 and not treated with DMT (2)a,ii less than 4 copies of SMN2 and not treated with DMT or (2)b. Patients diagnosed due to a sibling or alternative means (2)b,i 4 copies or more of SMN2 and not treated with DMT (2)b,ii less than 4 copies of SMN2 and not treated with DMT (3)Patients between 4 months and below 4 years at baseline. Inclusion of patients can be before 4 months of age (4)Parent(s)/legal guardian(s) able to provide written informed consent prior to the patient's participation in the study (5)Male or female Exclusion Criteria (Test cohort): 1. Any acute or chronic condition which, according to the investigator, significantly interferes with the assessments and/or the motor evolution 2. Currently enrolled in an experimental treatment study Inclusion criteria (Control): 1. Typically developing child 2. Participant between 6 months and 4 years at inclusion 3. Parent(s)/legal guardian(s) able to provide written informed consent prior to the participation in the study 4. Male or female Exclusion criteria (Control): (1)Any acute or chronic condition which, according to the investigator, significantly interferes with the assessments and/or the motor evolution

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal muscular atrophy (SMA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

spinal muscular atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal muscular atrophy (SMA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Oxford

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.